Page 6 - டெக்சாஸ் இதய அரித்மியா நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioSig Technologies Inc completes enrollment in PURE EP 2 0 clinical trial

BioSig Technologies Inc completes enrollment in PURE EP 2 0 clinical trial
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

United statesDavid medical centerHeart rhythm societyBiosig technologies incMayo foundation for medical educationTexas cardiac arrhythmia institute at stDrug administrationTexas cardiac arrhythmia instituteMedical centerMayo clinic florida campusMassachusetts general hospitalMayo foundationMedical educationHeart rhythmஒன்றுபட்டது மாநிலங்களில்டேவிட் மருத்துவ மையம்

NA Proactive news snapshot: Duos Technologies Group Inc, Argentina Lithium & Energy Corp, PlantX Life Inc, ImagineAR Inc, Byrna Technologies Inc, Elys Game Technology Corp UPDATE …

NA Proactive news snapshot: Duos Technologies Group Inc, Argentina Lithium & Energy Corp, PlantX Life Inc, ImagineAR Inc, Byrna Technologies Inc, Elys Game Technology Corp UPDATE …
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomKirkland lakeBritish columbiaSan diegoCooper mineMinas geraisCity ofPerth and kinrossRodney cooperYoshi tylerMatthew grahamKevin pavlovLouisf centofantiMark duffQuinton hennigh

Abbott Laboratories (NYSE:ABT), (BSGM) - The Future of Medicine is Here: Bioelectronic Medicine

Share: The medical technology industry is an integral part of the healthcare sector, with life-saving devices being developed to address the prevention, diagnosis, and treatment of diseases and illnesses. Many investors look to major players in the space like Medtronic (NYSE: MDT), Johnson & Johnson (NYSE: JNJ), and Abbott Laboratories (NYSE: ABT) to innovate and make forward strides in the healthcare industry. But there are many smaller, lesser-known companies at the forefront of medical device innovation, too. One of those companies making waves in the industry is BioSig Technologies (Nasdaq: BSGM). BioSig’s debut product, the PURE EP system, aims to dramatically improve cardiovascular health by delivering an advanced signal acquisition and processing platform that sets a new standard in electrophysiology (EP). This cardiology sector diagnoses and treats rapid heart rhythms, or arrhythmias. BioSig has developed a non-invasive technology that provides specific signal inf

New yorkUnited statesUniversity hospitalDavid medical centerAmerican heart associationPresbyterian weill cornell medical centerTexas cardiac arrhythmia instituteUniversity of pennsylvaniaAbbott laboratoriesBiosig technologiesMayo clinicMedical centerMassachusetts generalWeill cornell medical centerMichigan medicineHouston methodist

TCAI leader participates in clinical trial for catheter that may prevent rare, life-threatening complication during cardiac ablation

Share this article Share this article AUSTIN, Texas, Feb. 12, 2021 /PRNewswire/ A physician with the Texas Cardiac Arrhythmia Institute (TCAI) at St. David s Medical Center is among the first in the world to participate in a clinical trial to evaluate the safety and efficacy of a new cardiac-specific catheter used during pulsed field ablation (PFA), a new approach to treating patients with atrial fibrillation (A Fib). Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, recently participated in the first-in-human trials of this catheter in Europe.

United statesAndrea nataleStacy slaydenDavid medical centerTexas cardiac arrhythmia institute at stTexas cardiac arrhythmia instituteMedical centerCardiac arrhythmia instituteTexas cardiac arrhythmia institute at st davids medical centerஒன்றுபட்டது மாநிலங்களில்ஆண்ட்ரியா நடேல்நிலைத்தன்மை ஸ்லேடன்டேவிட் மருத்துவ மையம்டெக்சாஸ் இதய அரித்மியா நிறுவனம் இல் ஸ்டம்ப்டெக்சாஸ் இதய அரித்மியா நிறுவனம்மருத்துவ மையம்

TCAI physicians participate in clinical trial for potential life-saving device for patients with heart rhythm disorders

Share this article Share this article AUSTIN, Texas, Feb. 5, 2021 /PRNewswire/ Physicians with the Texas Cardiac Arrhythmia Institute (TCAI) at St. David s Medical Center are among the first in the world to participate in a clinical trial to evaluate a new esophageal protection device designed to make ablation procedures safer for patients with atrial fibrillation (A Fib), the most common type of cardiac arrhythmia. Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., cardiac electrophysiologist at TCAI, recently participated in the first-in-human trials in Europe.

United statesAmin al ahmadAndrea nataleStacy slaydenDavid medical centerTexas cardiac arrhythmia institute at stTexas cardiac arrhythmia instituteMedical centerCardiac arrhythmia instituteTexas cardiac arrhythmia institute at st davids medical centerஒன்றுபட்டது மாநிலங்களில்ஆண்ட்ரியா நடேல்நிலைத்தன்மை ஸ்லேடன்டேவிட் மருத்துவ மையம்டெக்சாஸ் இதய அரித்மியா நிறுவனம் இல் ஸ்டம்ப்டெக்சாஸ் இதய அரித்மியா நிறுவனம்